Clinical trials: Grade IV Glioma
Glioblastoma Multiforme
Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM)
Blood samples will be obtained from newly diagnosed GBM patients treated with combined radiotherapy (RT), temozolomide (TMZ) and bevacizumab (BEV) at specific time points.
- Trial name
- NCT01091792
- Testing
- Bevacizumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Diffuse Glioma, Diffuse Glioma, Grade I
Administration of Repurposed Ketoconazole in Glioma Patients
This early phase 1 clinical trial tests whether ketoconazole, an antifungal drug, can penetrate primary glioma brain tumors through the blood-brain barrier at levels sufficient to disrupt tumor growth, based on preclinical…
- Conditions
- Diffuse Glioma, Diffuse Glioma, Grade I, Diffuse Glioma, Grade II, Diffuse Glioma, Grade III
- Trial name
- NCT07585851
- Testing
- Ketoconazole
- Where
- Indonesia
- Volunteers
- 80 people
- Sponsor
- Universitas Padjadjaran
Malignant Glioma
Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
The main purpose of this study is to evaluate the safety, and tolerability of nivolumab, ipilimumab, and bevacizumab given in combination with hypofractionated stereotactic re-irradiation of recurrent high grade gliomas.
- Trial name
- NCT02829931
- Testing
- Hypofractionated Stereotactic Irradiation, Nivolumab, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Melanoma, Non Small Cell Lung Cancer
Dabrafenib and/or Trametinib Rollover Study
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have…
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
- Trial name
- NCT03340506
- Testing
- dabrafenib, trametinib
- Where
- 38 sites in United States, Argentina and 13 more
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Adult Anaplastic (Malignant) Meningioma, Adult Anaplastic Astrocytoma
Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases
This pilot clinical trial compares gadobutrol with standard of care contrast agents, gadopentetate dimeglumine or gadobenate dimeglumine, before dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) in diagnosing…
- Conditions
- Adult Anaplastic (Malignant) Meningioma, Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma
- Trial name
- NCT02967380
- Testing
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Gadobenate Dimeglumine, Gadobutrol
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Southern California
GBM, Glioblastoma
PVSRIPO for Recurrent Glioblastoma (GBM)
Purpose of the Study: To determine the maximally tolerated dose (MTD) and the Recommended Phase 2 Dose (RP2D) of PVSRIPO when delivered intracerebrally by convection-enhanced delivery (CED).
- Conditions
- GBM, Glioblastoma, Glioma, Malignant Glioma
- Trial name
- PVSRIPO (NCT01491893)
- Testing
- Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Istari Oncology, Inc.
Recurrent Glioblastoma (WHO-Grade IV Glioma)
Microsurgical Resection Combined With Photodynamic Therapy for Recurrent Glioblastoma
This single-center, prospective, single-arm, open-label clinical study evaluates the effectiveness and safety of microsurgical resection combined with photodynamic therapy (PDT) in patients with recurrent glioblastoma (GBM).
- Trial name
- PDT-rGBM (NCT07832448)
- Testing
- Hematoporphyrin Injection (Hiporfin), Microsurgical Tumor Resection, 630-nm Semiconductor Laser
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Yonggao Mou
Primary Glioblastoma
A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma
The primary objective of this clinical trial is to determine the safety and tolerability of two doses of light in intraoperative PDT added to standard of care; temozolomide-based chemotherapy in male and female patients aged 18…
- Trial name
- NCT05736406
- Testing
- 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2, 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 400 J/cm^2
- Where
- 2 sites in United States, France
- Volunteers
- 12 people
- Sponsor
- Hemerion Therapeutics
Glioblastoma, IDH1 Gene Mutation
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma that is newly diagnosed or has come back.
- Conditions
- Glioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation, Low Grade Glioma
- Trial name
- PNOC017 (NCT03749187)
- Testing
- PARP Inhibitor BGB-290, Temozolomide (TMZ)
- Where
- 11 sites in United States
- Volunteers
- 78 people
- Sponsor
- University of California, San Francisco
Glioma
Intratumorally-Administered Topotecan Using CED in High Grade Glioma Undergoing Stereotactic Biopsy
The purpose of this study is to determine if treatment with topotecan by an alternative method, direct delivery into brain tumors, is safe and well tolerated.
- Trial name
- NCT03193463
- Testing
- Topotecan (<=8cc), Topotecan (>8cc), Cleveland Multiport Catheter
- Sponsor
- Michael Vogelbaum, MD, PhD
Brain and Central Nervous System Tumors, Lymphoma
Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma
Phase II trial to study the effectiveness of rebeccamycin analogue in treating children who have solid tumors or non-Hodgkin's lymphoma.
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma
- Trial name
- NCT00006102
- Testing
- becatecarin
- Where
- 226 sites in United States, Australia and 5 more
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status
CENTRIC is a Phase 3 clinical trial assessing efficacy and safety of the investigational integrin inhibitor, cilengitide, in combination with standard treatment versus standard treatment alone in newly diagnosed glioblastoma…
- Trial name
- CENTRIC (NCT00689221)
- Testing
- Cilengitide, Temozolomide, Radiotherapy
- Where
- 2 sites in United States, Germany
- Volunteers
- 545 people
- Sponsor
- EMD Serono
Recurrent Glioma, Recurrent WHO Grade 2 Glioma
Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment
This phase II trial tests how well erdafitinib works in controlling IDH-wild type (WT), FGFR-TACC gene fusion positive gliomas that have come back after a period of improvement (recurrent) or that are growing, spreading, or…
- Conditions
- Recurrent Glioma, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma
- Trial name
- NCT05859334
- Testing
- Biospecimen Collection, Erdafitinib, Magnetic Resonance Imaging
- Where
- 27 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Glioblastoma, Recurrent Gliosarcoma
Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma
This is a phase 0/1 dose-escalation trial to determine the maximum tolerated dose of Mycophenolate Mofetil (MMF) when administered with radiation, in patients with glioblastoma or gliosarcoma.
- Conditions
- Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV, Newly Diagnosed Glioblastoma
- Trial name
- NCT04477200
- Testing
- Mycophenolate Mofetil, Radiation Therapy, Re-resection (as part of standard of care)
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Michigan Rogel Cancer Center
Glioblastoma Multiforme
Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM
This study aims to investigate effect of Nivolumab and Temozolomide vs Temozolomide alone on overall survival in newly diagnosed elderly patients with glioblastoma.
- Trial name
- NUTMEG (NCT04195139)
- Testing
- Nivolumab, Temozolomide
- Where
- 20 sites in United States, Australia
- Volunteers
- 103 people
- Sponsor
- University of Sydney
Glioblastoma (GBM), Brain Metastasases
A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases
This will be an open-label Phase 0/1 study that will enroll approximately 15 participants, 9 participants with recurrent WHO Grade 4 glioma (rGBM) and 6 participants with brain metastases, who will receive the investigational…
- Trial name
- NCT07268053
- Testing
- Risvutatug rezetecan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Nader Sanai
Recurrent High-grade Glioma, Grade III Astrocytoma
Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma
This is a Phase I study of ex vivo expanded CD34+ hematopoietic stem cells (exHSCs) plus nivolumab in pediatric patients with histologically confirmed diagnosis of a non-brainstem high-grade glioma (NB-HGG, WHO Grade III or IV…
- Conditions
- Recurrent High-grade Glioma, Grade III Astrocytoma, Oligodendroglioma, Oligoastrocytoma
- Trial name
- Peds CHAMP1ON (NCT07031765)
- Testing
- exHSC, Nivolumab, Resection or biopsy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Florida
MGMT-unmethylated Glioblastoma (GBM), IDH Wildtype Glioblastoma
Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas
This clinical trial is designed with two treatment stages: Stage 1: one cycle of study drug treatment prior to initiation of first-line standard radiation in all study participants.
- Trial name
- NCT07778602
- Testing
- avutometinib and defactinib for 3 weeks on/1 week off, MGMT-unmethylated GBM with Radiation
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 22 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma
Biomarkers for Prognosis of Glioblastoma (GBM)
The purpose of this study is: 1. To learn if (MMP-2, MMP-9 and NGAL) which are substances found in blood and urine associated with tumors, can be used as tumor markers in the management and treatment of glioblastoma. 2.
- Trial name
- NCT01493219
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Nebraska
Glioblastoma Multiforme, Astrocytoma, Grade IV
T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma
The goal of this clinical trial is to test a combined therapy approach (allogeneic cytomegalovirus [CMV]-specific T cells and pembrolizumab) in patients with brain cancer.
- Trial name
- TCaP (NCT06157541)
- Testing
- Allogeneic cytomegalovirus-specific T cells, Pembrolizumab
- Where
- 4 sites in Australia
- Volunteers
- 58 people
- Sponsor
- Queensland Institute of Medical Research